USTEKINUMAB

SYNONYMS Ustekinumab (rmc)

BRAND NAME STELARA

DRUG CLASS Immunosuppressant, cytokine modulator, monoclonal antibody (human)

AVAILABILITY Vial for subcutaneous use contains 45 mg/0.5 mL of ustekinumab. Also contains histidine/histidine hydrochloride, sucrose and polysorbate-80. The solution is clear to slightly opalescent and colourless to light yellow.¹

Vial for intravenous use contains 130 mg/26 mL of ustekinumab. Also contains histidine, histidine hydrochloride, sucrose, polysorbate-80, L-methionine and disodium edetate. The solution is clear and colourless to light yellow.¹

pH 6¹

PREPARATION Not required for subcutaneous injection. Do not shake the vial.¹

For IV infusion: calculate the volume of the dose required and withdraw then discard this amount from a 250 mL bag of sodium chloride 0.9%. Add the dose to the bag so that the final volume is 250 mL. Invert the bag and mix gently. Do not shake.¹

STABILITY Vial: store at 2 to 8 °C. Do not freeze. Protect from light.¹

Infusion solution: stable for 4 hours at below 25 °C.¹

ADMINISTRATION

IM injection Not recommended

SUBCUT injection Inject into the thigh, abdomen or upper arms.¹² Suitable for self-administration in selected patients.¹

IV injection Not recommended

IV infusion Infuse over at least an hour. Use a low protein-binding 0.2 micrometer filter.¹

COMPATIBILITY Sodium chloride 0.9%

INCOMPATIBILITY No information

SPECIAL NOTES Hypersensitivity reactions including rash and urticaria may occur.¹

Anaphylactic reactions have been reported.¹

Given by subcutaneous injection for plaque psoriasis and psoriatic arthritis. For Crohn’s disease, the first dose is given by IV infusion, then subsequent doses are given by subcutaneous injection.

REFERENCES


WARNING

The occupational hazard of intermittent low dose exposure to ustekinumab is not known. Wear a mask and gloves when reconstituting the vial and preparing the infusion solution to minimise exposure.